

Diagnosis and management of headaches in young people and adults

4th Guideline Development Group Meeting

National Clinical Guideline Centre

Date and Time: ***8th April 2011 10:00 – 16:00***

Place: *NCGC, 180 Great Portland Street, London*

GDG Present: Martin Underwood (Chair)
Ria Bhola
Mark Dunne-Willows
Carole Gavin
Devina Halsall
Kay Kennis
David Kernick
Manjit Matharu
Peter May
Wendy Thomas

NCGC Present: Sara Buckner
Serena Carville
Zahra Naqvi
Norma O'Flynn
Smita Padhi
Tim Reason
Carlos Sharpin

In attendance:

NICE Staff:
Claire Turner (CT)

Observers:
Samantha Fulcher NCGC
Lee-Yee Chong NCGC

Minutes

1. **Introductions and apologies.** The Chair welcomed everyone to the meeting and noted apologies for Brendan Davies, Sam Chong and William Whitehouse.

The GDG were reminded to update their declarations of interest if any changes had occurred since the last meeting. No new declarations of interest were noted.

The minutes of GDG 3 were agreed as an accurate reflection of the meeting, there were no matters arising.

2. **Acute pharmacological treatment of primary headaches – direct comparisons. (Question 5)**
 - a) **Cluster headaches.**

SB presented the clinical evidence for the acute pharmacological treatment of cluster headaches. There was no economic evidence to present. The group discussed the evidence and drafted a recommendation.
 - b) **Tension type headaches.** SP presented the clinical evidence for the acute pharmacological treatment of tension type headache. There was no economic evidence to present. The group discussed the evidence and drafted recommendations.
 - c) **Migraine.** SC presented clinical evidence for the acute pharmacological treatment of migraine. The group discussed the evidence and CS presented an explanation of a network meta-analysis as a possible next step to undertake mixed treatment comparisons for this review. It was agreed this would be done and presented at the next GDG.
3. **Economic Plan.** TR presented the plan for the economic model for acute pharmacological treatment of migraine. The group discussed the plan for the model and it was agreed some revisions would be made and discussed further with the economic subgroup prior to the next meeting.
4. **Protocols for agreement.** The GDG discussed and finalised some of the remaining protocols. The remainder will be reviewed at the next meeting.
5. **Any other business.** The GDG were informed of the upcoming technology appraisal scoping workshop for the use of botulinum toxin in the prophylaxis of chronic migraine. The GDG were encouraged to register for stakeholders if they had not already done so and send in any comments prior to 12th April.

Date, time and venue of the next meeting

Friday 13th May 2011, 10:00–16:00, National Clinical Guidelines Centre, 180 Great Portland Street, London